BTIG Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $55
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin initiates coverage on IDEAYA Biosciences (IDYA) with a Buy rating and sets a price target of $55.

March 08, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IDEAYA Biosciences receives a Buy rating from BTIG with a price target of $55.
The initiation of coverage by BTIG with a Buy rating and a high price target of $55 is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term. Analyst ratings, especially from reputable firms like BTIG, can significantly influence investor perception and stock performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100